FreshPatents.com Logo


new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)


Similar
Filing Names

Merck Sharp x26 Dohme Corp
Merck Sharp x26 Dohme Corporation
Merck Sharp x26 Dohme Corp And Northwestern University
Merck Sharp x26 Dohme Corp_20131212

Popular
Companies


Web
Adobe patents
Akamai patents
Amazon patents
Apple patents
Ebay patents
Facebook patents
Google patents
IBM patents
Linkedin patents
Microsoft patents
Oracle patents
Red Hat patents
Yahoo patents

Food/Health
Adidas
Nike patents
Pfizer patents
Monsanto patents
Medtronic patents
Kraft patents

Transportation
Boeing patents
Tesla Motors patents

Telecom
Qualcomm patents
Motorola patents
Nokia patents
RIMM patents

Industrial/Electronics
AMD
Applied Materials
Seagate patents
General Electric
Caterpillar patents
Samsung
Wal-mart patents

Ticker Symbols

Merck Sharp & Dohme Corp patents


      
Recent patent applications related to Merck Sharp & Dohme Corp. Merck Sharp & Dohme Corp is listed as an Agent/Assignee. Note: Merck Sharp & Dohme Corp may have other listings under different names/spellings. We're not affiliated with Merck Sharp & Dohme Corp, we're just tracking patents.

ARCHIVE: New 2014 2013 2012 2011 2010 2009 | Company Directory "M" | Merck Sharp & Dohme Corp-related inventors



Search recent Press Releases: Merck Sharp & Dohme Corp-related press releases
Count Application # Date Merck Sharp & Dohme Corp patents (updated weekly) - BOOKMARK this page
12012025303210/04/12Novel cationic lipids with short lipid chains for oligonucleotide delivery
22012020281908/09/12Combination therapy using a beta 3 adrenergic receptor agonists and an antimuscarinic agent
32014037002512/18/14 new patent  Uses of mammalian cytokines and agonists; related reagents
42014037113812/18/14 new patent  Inhibitors of hepatitis c virus replication
52014034997211/27/14Substituted pyrimidines
62014034884111/27/14Anti-gitr antibodies
72014034999811/27/14Pyrrolopyrimidines as janus kinase inhiitors
82014035000211/27/14Imidazopyridin-2-one derivatives
92014034307111/20/14Compositions and methods for treating cancer
102014033619611/13/14Phosphoric acid salts of sitagliptin
112014032927611/06/14Methods for increasing n-glycan occupancy and reducing production of hybrid n-glycans in pichia pastoris strains lacking alg3 expression
122014032351910/30/14Heterocyclic compounds as b-raf inhibitors for treatment of cancer
132014029620210/02/14Substituted piperidinyl compounds useful as gpr119 agonists
142014029622110/02/14Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use
152014029622210/02/14Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use
162014027501709/18/14Cgrp receptor antagonists
172014025681809/11/14Nano-suspension process
182014024428908/28/14Cold storage system for storing pharmaceutical product containers
192014023429608/21/14Stable formulations of antibodies to human programmed death receptor pd-1 and related treatments
202014023430108/21/14Modulation of pilr to treat immune disorders
212014023553708/21/14N-glycosylated insulin analogues
222014022562708/14/14Device for calibrating and verifying the integrity of resistivity-based sensing probes
232014022722308/14/14Pegylated interleukin-10
242014022725008/14/14Stable formulations of antibodies to tslp
252014022729008/14/14Method for increasing n-glycosylation site occupancy on therapeutic glycoproteins produced in pichia pastoris
262014022729208/14/14Anti-mcam antibodies and associated methods of use
272014022002708/07/141d05 pcsk9 antagonists
282014022138308/07/14Cetp inhibitors
292014021241207/31/14Use of il-33 antagonists to treat fibrotic disease
302014020656307/24/14Biomarkers for psoriasis
312014020664007/24/142'-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
322014020664107/24/14Remedy
332014020666507/24/14Selective glycosidase inhibitors and uses thereof
342014020667507/24/14Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use
352014020671507/24/14Preparation and use of compounds as protease inhibitors
362014020018007/17/14Method for producing proteins in pichia pastoris that lack detectable cross binding activity to antibodies against host cell antigens
372014020021307/17/142-spiro-substituted iminothiazines and their mono-and dioxides as bace inhibitors, compositions and their use
382014017015406/19/14Engineered anti-il-23r antibodies
392014017065806/19/14Mammalian cytokines; related reagents
402014017143706/19/14Oxazole derivatives useful as inhibitors of faah
412014017145606/19/14Fused tricyclic compounds as mtor inhibitors
422014017148006/19/14Crystalline polymorphic forms of an antidiabetic compound
432014016177006/12/142'-cyano substituted nucleoside derivatives and methods of use thereof useful for the treatment of viral diseases
442014016179806/12/14Anti-pcsk9 and methods for treating lipid and cholesterol disorders
452014014744205/29/14Use of il-23 antagonists for treatment of infection
462014014746105/29/14Polypeptides for inducing a protective immune response against staphylococcus aureus
472014014095405/22/14Methods of modulating cytokine activity; related reagents
482014014101205/22/14Engineered anti-tslp antibody
492014014144405/22/14Isolated mammalian monocyte cell genes; related reagents
502014014144505/22/14Isolated mammalian monocyte cell genes; related reagents
512014014211505/22/14Inhibitors of the renal outer medullary potassium channel
522014012836105/08/14Cyclic amide bace-1 inhibitors having a benzamide substituent
532014012836705/08/14Cycloalkyl-fused tetrahydroquinolines as crth2 receptor modulators
542014012836805/08/14Substituted cyclopropyl compounds, compositions containing such compounds, and methods of treatment
552014012003705/01/14Method for detection of amyloids beta oligomers in a fluid sample and uses thereof
562014011291904/24/14Interleukin-10 antibodies
572014011392004/24/14Tricyclic heterocycles useful as dipeptidyl peptidase-iv inhibitors
582014010588704/17/14Methods for modulating il-33 activity
592014010641304/17/14Immobilized transaminases and process for making and using immobilized transaminase
602014010734604/17/14Process for preparing chiral dipeptidyl peptidase-iv inhibitors
612014009356404/03/14Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with simvastatin
622014009387504/03/14Mammalian cytokines; receptors; related reagents and methods
632014008804803/27/14Diazeniumdiolate cyclohexyl derivatives
642014008088403/20/14Novel crystalline forms of a dipeptidyl peptidase-iv inhibitor
652014005789302/27/14Substituted cycloproply compounds, compositions containing such compounds and methods of treatment
662014005174002/20/14Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
672014004574602/13/14Antidiabetic tricyclic compounds
682014004582902/13/14Substituted 1,3-benzothiazol-2(3h)-ones and [1,3]thiazolo[5,4-b]pyridin-2(1h)-ones as positive allosteric modulators of mglur2
692014004583202/13/14Insulin-like growth factor-1 receptor inhibitors
702014003762702/06/14Modulation of pilr receptors to treat microbial infections
712014003894202/06/14Rorgammat inhibitors
722014003897002/06/14Bridged and fused antidiabetic compounds
732014003025501/30/14Methods of predicting cancer cell response to therapeutic agents
742014003076001/30/14Pavec
752014003125101/30/14Methods of classifying human subjects with regard to cancer prognosis
762014003134901/30/14Inhibitors of the renal outer medullary potassium channel
772014002366701/23/14Pyrrolidine-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
782014000518201/02/14Aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators
792013034451212/26/13Cd16a reporter assay for evaluation of adcc potential of biologics
802013033137212/12/13Cyclic amine substituted oxazolidinone cetp inhibitor
812013032323912/05/13Modulation of pilr receptors to treat sepsis
822013032324612/05/13Use of mdl-1 antagonists to treat spondylarthropathy
832013032325112/05/13Use of il-23 and il-17 antagonists to treat autoimmune ocular inflammatory disease
842013032448312/05/13Mammalian cell surface antigens; related reagents
852013032461012/05/13Cathepsin cysteine protease inhibitors
862013032472812/05/13Process for the preparation of an orexin receptor antagonist
872013031635411/28/13Mammalian cytokine; related reagents
882013029627811/07/13Diazeniumdiolate derivatives
892013028776310/31/13Combination therapy for treating cancer comprising an igf-1r inhibitor and an akt inhibitor
902013028021410/24/13Polycyclic heterocycle derivatives and methods of use thereof for the treatment of viral diseases
912013028147410/24/13Fused tricyclic inhibitors of mammalian target of rapamycin
922013026114010/03/13Tricyclic heterocycles useful as dipeptidyl peptidase-iv inhibitors
932013025167709/26/13Genetic markers associated with interferon-alpha response
942013024369209/19/13Fdg-pet evaluation of ewing's sarcoma sensitivity
952013023751809/12/13Novel compounds that are erk inhibitors
962013023085509/05/13Monocyte-derived nucleic acids and related compositions and methods
972013022558208/29/13Biaryl-spiroaminooxzaoline analogues as alpha 2c adrenergic receptor modulators
982013022583608/29/13Novel low molecular weight cyclic amine containing cationic lipids for oligonucleotide delivery
992013021657508/22/13Recombinant subunit dengue virus vaccine
1002013021769508/22/13Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
1012013021775608/22/13Rna interference mediated inhibition of gene expression using short interfering nucleic acids (sina)
1022013021776608/22/13Formulations for cathepsin k inhibitors
1032013020306008/08/13Mammalian genes; related reagents
1042013018927807/25/13Antagonists of pcsk9
1052013015794006/20/13Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
1062013015672906/20/13Mammalian receptor proteins; related reagents and methods
1072013015677106/20/13Fdf03 antibodies and uses thereof
1082013015036206/13/13Novel pyrazolo[1,5-a]pyrimidine derivatives as mtor inhibitors
1092013014385906/06/13Novel prolylcarboxypeptidase inhibitors
1102013013104105/23/13Spirocyclic compounds
1112013013104205/23/13Spiroxazolidinone compounds
1122013012200905/16/13Engineered anti-il-23p19 antibodies
1132013012320005/16/13Mammalian cell surface antigens; related reagents
1142013012323705/16/13Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
1152013011522305/09/13Antagonists of pcsk9
1162013011623105/09/13Tyrosine kinase inhibitors
1172013010973905/02/13Compositions and methods for short interfering nucleic acid inhibition of nav1.8
1182013009605304/18/13Posaconazole intravenous solution formulations stabilized by substituted beta-cyclodextrin
1192013007139003/21/13Method for preparing antibodies having improved properties
1202013006481703/14/13Engineered anti-il-23r antibodies
1212013005985003/07/13Aza-indole derivatives useful as modulators of faah
1222013005335202/28/13Diazeniumdiolate cyclopentyl derivatives
1232013004591402/21/13Biaryl spiroaminooxazoline analogues as alpha2c adrenergic receptor modulators
1242013004092902/14/13Novel prolylcarboxypeptidase inhibitors
1252013004093202/14/13Substituted aryl sulfone derivatives as calcium channel blockers
1262013003456102/07/13Isolated mammalian monocyte cell genes; related reagents
1272013003531202/07/13Cathepsin cysteine protease inhibiors
1282013002351501/24/13Novel spiropiperidine prolylcarboxypeptidase inhibitors
1292013001804801/17/13Oxazole derivatives useful as modulators of faah
1302013001252601/10/13Oxazole derivatives useful as modulators of faah
1312013000579701/03/13Endosomolytic poly(amidoamine) disulfide polymers for the delivery of oligonucleotides
1322013000451801/03/13Cyclic amine bace-1 inhibitors having a benzamide substituent
1332012032967912/27/12Eukaryotic cell display systems
1342012031532112/13/12Immunological methods and compositions for the treatment of alzheimer's disease
1352012031620012/13/12Pyridone derivatives
1362012027724011/01/12Substituted aminotetrahydrothiopyrans and derivatives thereof as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes
1372012026477710/18/12Oxadiazole beta carboline derivatives as antidiabetic compounds
1382012023200709/13/12Method for producing proteins in pichia pastoris that lack detectable cross binding activity to antibodies against host cell antigens
1392012023208609/13/12Fused tricyclic compounds with adenosine a2a receptor antagonist activity
1402012022588609/06/12Novel pyrrolidine derived beta 3 adrenergic receptor agonists
1412012021484608/23/12Hexahydrocyclopentyl[f]indazole pyridyl ethanols and derivatives thereof as selective glucocorticoid receptor modulators
1422012021484708/23/122-[1-phenyl-5-hydroxy-4a-substituted-hexahydrocyclopenta[f]indazol-5-yl]ethyl phenyl derivatives as glucocorticoid receptor ligands
1432012020188508/09/12Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with pioglitazone
1442012019690108/02/12Tertiary amide orexin receptor antagonists
1452012019070107/26/12Renin inhibitors
1462012017868107/12/12Bipiperidinyl compounds, compositions, containing such compounds and methods of treatment
1472012017875007/12/12Niacin receptor agonists, compositions containing such compounds and methods of treatment
1482012017239707/05/12Hexahydrocyclopenta[f]indazole 5-yl ethanols and derivatives thereof as selective glucocorticoid receptor modulators
1492012016415806/28/12Anti-addl monoclonal antibody and use thereof
1502012015743806/21/12Pyranyl aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators
1512012015743206/21/12Novel pyrrolidine derived beta 3 adrenergic receptor agonists
1522012014277006/07/12Pharmaceutical compositions of hdac inhibitors and chelatable metal compounds, and metal-hdac inhibitor chelate complexes
1532012014269406/07/12Substituted 4-hydroxypyrimidine-5-carboxamides
1542012014275206/07/12Hiv protease inhibitors
1552012013601205/31/12Amino tetrahydro-pyridopyrimidine pde10 inhibitors
1562012012162405/17/12Hepatitis c virus ns3 protease inhibitors
1572012011913005/17/12Diaphragm valve with improved sealing performance and leak detection
1582012012150805/17/12Radiolabeled cgrp antagonists
1592012012158005/17/12Methods for producing high concentration lyophilized pharmaceutical formulations
1602012012289905/17/12Piperidinone carboxamide azaindane cgrp receptor antagonists
1612012012290005/17/12Piperidinone carboxamide azaindane cgrp receptor antagonists
1622012012291105/17/12Piperidinone carboxamide azaindane cgrp receptor antagonists
1632012011589405/10/12Imidazole derivatives useful as modulators of faah and as faah imaging agents
1642012011592105/10/12Fluoro substituted cycloalkanoindoles, compositions containing such compounds and methods of treatment
1652012010860005/03/12Substituted 4-hydroxypyrimidine-5-carboxamides
1662012009500104/19/12Substituted-1,3,8-triazaspiro[4.5]decane-2,4-diones
1672012009505504/19/12Hexahydrocyclopentyl[f]indazole 5-hydroxymethyl ethanols and derivatives thereof as selective glucocorticoid receptor modulators
1682012008348304/05/12Inhibitors of hepatitis c virus replication
1692012008267904/05/12Antagonists of pcsk9
1702012008268004/05/12Antagonists of pcsk9
1712012007679903/29/12Antagonists of pcsk9
1722012007796403/29/12Antagonists of pcsk9
1732012005318103/01/12Pyrrolidine-derived beta 3 adrenergic receptor agonists
1742012004097802/16/12Heterocyclic fused cinnoline m1 receptor positive allosteric modulators
1752012003460802/09/12Microrna as a biomarker of pancreatic islet beta-cell engagement
1762012003521402/09/12Renin inhibitors
1772012003524702/09/12Rna interference mediated inhibition of signal transducer and activator of transcription 6 (stat6) gene expression using short interfering nucleic acid (sina)
1782012002894002/02/12Functionally selective azanitrile alpha-2c adrenoreceptor agonists
1792012002905402/02/12Rna interference mediated inhibition of gata binding protein 3 (gata3) gene expression using short intefering nucleic acid (sina)
1802012002214301/26/12Rna interference mediated inhibition of the thymic stromal lymphopoietin (tslp) gene expression using short interfering nucliec acid (sina)
1812012002107401/26/12P2x3, receptor antagonists for treatment of pain
1822012002194801/26/12Surface display of whole antibodies in eukaryotes
1832012002214201/26/12Rna interference mediated inhibition of signal transducer and activator of transcription 1 (stat1) gene expression using short interfering nucleic acid (sina)
1842012001601001/19/12Rna interference mediated inhibition of btb and cnc homology 1, basic leucine zipper transcription factor 1 (bach1) gene expression using short interfering nucleic acid (sina)
1852012001601101/19/12Rna interference mediated inhibition of connective tissue growth factor (ctgf) gene expression using short interfering nucleic acid (sina)
1862012000958001/12/12Methods for quantitating small rna molecules
1872012001019301/12/12Cgrp receptor antagonists
1882012001027201/12/12Rna interference mediated inhibition of apoptosis signal-regulating kinase 1 (ask1) gene expression using short interfering nucleic acid (sina)
1892012000428101/05/12Rna interference mediated inhibition of the nerve growth factor beta chain (ngfb) gene expression using short interfering nucleic acid (sina)
1902012000428201/05/12Rna interference mediated inhibition of the intercellular adhesion molecule 1 (icam-1) gene expression using short interfering nucleic acid (sina)
1912012000428001/05/12Rna interference mediated inhibition of the high affinity 1 ge receptor alpha chain (fc epsilon r1 alpha) gene expression using short interfering nucleic acid (sina)
1922011031291112/22/11Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
1932011030107912/08/11Neuromedin u receptor agonists and uses thereof
1942011029469612/01/11Methods for characterizing agonists and partial agonists of target molecules
1952011029473512/01/11Mechanism of neuromedin u action and uses thereof
1962011029477712/01/11Beta-lactamase inhibitors
1972011026353310/27/11Novel cyclic benzimidazole derivatives useful as anti-diabetic agents
1982011025059110/13/11Method of designing sirnas for gene silencing
1992011025120710/13/11Biaryl-spiroaminooxazoline analogues as alpha 2c adrenergic receptor modulators
2002011024051110/06/11Packaging for oxygen-sensitive pharmaceutical products
2012011023763409/29/11Novel crystalline forms of an inhibitor of 11-beta-hydroxysteroid dehydrogenase type 1
2022011022950809/22/11Polypeptides for inducing a protective immune response against staphylococcus aureus
2032011023049809/22/11Biaryl carboxamides
2042011023052609/22/11Thiazolyl mglur5 antagonists and methods for their use
2052011022419309/15/11Inhibitors of diacylglycerol acyltransferase
2062011022413409/15/11Macrocyclic quinoxaline compounds as hcv ns3 protease inhibitors
2072011022419509/15/11Heterocyclic compounds as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
2082011021817409/08/11Novel cyclic benzimidazole derivatives useful as anti-diabetic agents
2092011021820209/08/11Soluble guanylate cyclase activators
2102011020773708/25/11Substituted bicyclic amines for the treatment of diabetes
2112011020794208/25/11Intermediate compounds for the preparation of trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1h-dibenz[2,3:6,7]-oxepino[4,5-c]pyrrole
2122011020162108/18/11Angiotensin ii receptor antagonists
2132011019595708/11/11Substituted diazepan orexin receptor antagonists
2142011019030808/04/11Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
2152011019034608/04/11Diphenyl substituted alkanes as flap inhibitors
2162011017805907/21/111,3-oxazolidin -2-one derivatives useful as cetp inhibitors
2172011017811707/21/11Oxazolobenzimidazole derivatives
2182011017881907/21/11Devices and methods for determining a patient's propensity to adhere to a medication prescription
2192011017220507/14/11Monocyclic amide cgrp receptor antagonists
2202011015230406/23/11Spiroazaindoles
2212011013676906/09/11Method of treating men with testosterone supplement and 5alpha-reductase inhibitor
2222011012466105/26/11Oxazolobenzimidazole derivatives
2232011011833705/19/11Method of using compositions comprising mir-192 and/or mir-215 for the treatment of cancer
2242011011197605/12/11Microrna biomarkers of tissue injury
2252011011206405/12/11Pyridyl amide t-type calcium channel antagonists
2262011011207705/12/11Quinolizidinone m1 receptor positive allosteric modulators
2272011007672103/31/11Efficient production of heterologous proteins using mannosyl transferase inhibitors
2282011006566903/17/11Oxazolobenzimidazole derivatives
2292011006577803/17/11Rna interference mediated inhibition of muscarinic colinergic receptor gene expression using short interfering nucleic acid (sina)
2302011005392703/03/11Nanoparticle formation via rapid precipitation
2312011004614502/24/11Quinolizidinone m1 receptor positive allosteric modulators
2322011002151601/27/11Monocyclic cgrp receptor antagonists
2332011001586901/20/11Methods and gene expression signature for assessing growth factor signaling pathway regulation status
2342010033017712/30/10Pharmaceutical compositions of a combination of metformin and a dipeptidyl peptidase-iv inhibitor
2352010032402312/23/10Imidazobenzazepine cgrp receptor antagonists
2362010032402412/23/10Quinolizidinone m1 receptor positive allosteric modulators
2372010032408812/23/10Fused pyridone m1 receptor positive allosteric modulators
2382010032409212/23/10Pyridyl and pyrimidinyl derivatives as histone deacetylase inhibitors
2392010031164912/09/10Substituted imidazole 4-carboxamides as cholecystokinin-1 receptor modulators
2402010029826911/25/10Prodrugs of cgrp receptor antagonists
2412010029830311/25/10Cgrp receptor antagonists
2422010029224111/18/103,5-substituted-1,3-oxazolidin-2-one derivatives
2432010026770710/21/10Tyrosine kinase inhibitors
2442010024902409/30/10Cetp inhibitors
2452010022790909/09/10Compositions comprising mir34 therapeutic agents for treating cancer
2462010020996008/19/10Method for measuring mitochondrial membrane potential in vertebrate cells
2472010021108108/19/10Microdrive and modular microdrive assembly for positioning instruments in animal bodies
2482010018482507/22/10Rna interference mediated inhibition of protein tyrosine phosphatase-1b (ptp-1b) gene expression using short interfering nucleic acid (sina)
2492013033137212/12/13Cyclic amine substituted oxazolidinone cetp inhibitor


ARCHIVE: New 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Merck Sharp & Dohme Corp in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Merck Sharp & Dohme Corp with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###

     SHARE
  
         



Key IP Translations - Patent Translations